GLUcose Transport and REnalPROtection in Chronic Kidney Disease

Summary

This is a single-center, double blind, randomized, parallel-arms study designed to investigate the effects of a six-month treatment with the SGLT2i dapagliflozin on markers of kidney senescence, inflammation and tubulointerstitial damage compared to placebo. These mechanisms of renal damage will be investigated in proximal tubular epithelial cells (PTECs) isolated from urine from patients with CKD with or without T2DM and in renal biopsy specimens in a subgroup of patients with diabetic kidney disease.

Timeline

Start

2021-04-13

Primary completion

2024-09-30

Completion

2024-09-30

Publications

• Russo E, Cappadona F, Maccio L, Di Vincenzo J, Piaggio M, Verzola D, Chirco G, Garibotto G, Esposito P, Viazzi F. Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial. High Blood Press Cardiovasc Prev. 2026 Jan;33(1):117-126. doi: 10.1007/s40292-025-00764-3. Epub 2025 Dec 9.
• Russo E, Venturelli E, Di Vincenzo J, Maccio L, Esposito P, Cappadona F, Ferrazzi G, Grillo R, Damasio MB, Garibotto G, Viazzi F. Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients: Analysis of Blood Oxygenation Level-Dependent Magnetic Resonance Imaging Renal Data from the Randomized Glucose Transport and Renal Protection in CKD Trial. Kidney360. 2026 Mar 1;7(3):535-546. doi: 10.34067/KID.0000001015. Epub 2025 Nov 12.

Drugs

Indications